Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also designs, manufactures, and sells neural interface technologies, including microelectrode arrays, custom designed probes, and electrode instrumentation and accessories; and develops Virtis, a sacral neuromodulation system for the treatment of chronic urinary retention and overactive bladder. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVTR
CUSIPN/A
Phone214-474-3103
Debt
Debt-to-Equity Ratio0.61
Current Ratio5.51
Quick Ratio5.15
Price-To-Earnings
Trailing P/E Ratio-3.80
Forward P/E Ratio-4.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.84 million
Price / Sales7.12
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book3.58
Profitability
EPS (Most Recent Fiscal Year)($4.22)
Net Income$-44,600,000.00
Net Margins-112.42%
Return on Equity-72.39%
Return on Assets-43.04%
Miscellaneous
Employees195
Outstanding Shares14,150,000
Market Cap$230.27
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) released its earnings results on Wednesday, May, 2nd. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.89) by $0.05. The business had revenue of $10.57 million for the quarter, compared to analysts' expectations of $9.71 million. Nuvectra had a negative net margin of 112.42% and a negative return on equity of 72.39%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What price target have analysts set for NVTR?
3 equities research analysts have issued 12-month target prices for Nuvectra's shares. Their forecasts range from $12.00 to $27.00. On average, they expect Nuvectra's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price. View Analyst Ratings for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include SurModics (SRDX), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Endologix (ELGX), MiMedx Group (MDXG), Neuronetics (STIM), Antares Pharma (ATRS), Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Orthopediatrics (KIDS), Utah Medical Products (UTMD), Cytosorbents (CTSO), Westaim (WEDXF) and Accuray (ARAY).
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Mr. Scott F. Drees, CEO & Director (Age 60)
- Mr. Joseph Paul Hanchin, Pres (Age 56)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 62)
- Dr. Norbert Kaula Ph.D., Chief Technology Officer
- Ms. Melissa G. Beare, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43)
Has Nuvectra been receiving favorable news coverage?
Headlines about NVTR stock have trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nuvectra earned a news sentiment score of 0.21 on Accern's scale. They also assigned media headlines about the company an impact score of 44.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $16.02.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $230.27 million and generates $31.84 million in revenue each year. The company earns $-44,600,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. Nuvectra employs 195 workers across the globe.
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
